Physician profile
Reshma Markan
NPI 1366535783
$11,057.77
in general payments reported to CMS, 2019-2025
58 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,715 · 2020: $2,978 · 2021: $888 · 2022: $973 · 2023: $726 · 2024: $1,260 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,502.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $3,317.05 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $1,352.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $524.55 | 2019-2024 | Farxiga |
| Amgen INC. | $523.92 | 2019-2025 | Evenity, Tepezza, Prolia |
| Dexcom, INC. | $463.51 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.86 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $363.08 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $303.72 | 2019-2025 | |
| Corcept Therapeutics | $275.73 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $260.93 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Valeritas, INC. | $197.99 | 2019 | |
| Antares Pharma, INC. | $185.74 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Avvisto Therapeutics, LLC | $179.66 | 2025 | Cycloset |
| Kyowa Kirin, INC. | $176.12 | 2025 | |
| Abbott Laboratories | $164.39 | 2019-2025 | Freestyle Libre 3 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Markan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.